ArticleJournal of nanobiotechnology2025
Targeted blockade of extracellular vesicles-mediated profibrotic vicious circle using EVs-based dual-drug delivery system to prevent liver fibrosis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell and spatial transcriptomics reveal Thbs1-CD36 crosstalk between Kupffer and hepatic stellate cells following mesenchymal stem cell-derived small extracellular vesicles transplantation, alleviating liver fibrosis.Journal of nanobiotechnology · 2026Article
- CombinedFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Liver fibrosis, caused by various chronic liver injuries, is one of the major causes of morbidity and mortality worldwide, but there is no efficient treatments in clinic until now. Cell-cell interactions in the injured liver microenvironment play critical roles in hepatic stellate cells (HSCs) activation and excessive extracellular matrix (ECM) deposition, but the exact mechanism involved and specific therapies remain elusive. Here, we report that an extracellular vesicles (EVs)-mediated profibrotic vicious circle might contribute to HSCs activation during the early stages of liver fibrosis development. In brief, increased EVs secretion was observed in patients with liver cirrhosis, mice with liver fibrosis, and injured hepatocytes, whereas pharmacological inhibition of EVs secretion partially alleviated liver fibrosis in mice in vivo. However, the injured hepatocytes-derived EVs (IH-EVs) alone only promoted HSCs proliferation but not ECM deposition. The robust activation of HSCs requires the participation of liver macrophages, which can engulf IH-EVs and secrete various pro-inflammatory and pro-fibrotic factors, thereby sustaining hepatocytes injury and providing costimulation signals to promote HSCs activation and excessive ECM production. Mechanistically, IH-EVs might synergize with macrophages to promote HSCs proliferation by activating the PI3K-AKT and JAK-STAT pathways. We further developed a liver-targeted dual-drug delivery system using normal liver tissue-derived EVs (LT-EVs), which display significant antifibrotic effects in vivo by synergistically suppressing liver EVs secretion and macrophages activation. This study reveals an endogenous EVs-mediated pro-fibrotic mechanism in early liver fibrosis, and provides a potential therapeutic strategy for treating liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.